Semaglutide (Ozempic) vs Semaglutide (Rybelsus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT06050577 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Semaglutide (Ozempic) | Semaglutide (Rybelsus) |
|---|---|---|
| HbA1c, change | -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
| -1.6% vs -0.2%−1.4 vs placeboNCT0410954734 other results
|
| Body weight, change (kg) | -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
| -4.2 vs -1.3−2.9 vs placeboNCT0391432639 other results
|
| HbA1c below 7% | 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
| —Not posted · NCT04596631, expected 2026-08 |
| Fasting plasma glucose, change | -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
| -1.9 vs -0.7−1.2 vs placeboNCT0286341939 other results
|
| 3-point MACE (% with event) | 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
| 12% vs 13.8%−1.8 vs placeboNCT039143261 other result
|
HbA1c, change
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.8% vs -1.1% NCT02648204
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.3% vs -0.6% NCT01930188
- -1.5% vs -1.1% NCT02648204
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.7% NCT05514535
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.0% vs -0.7% NCT02207374
- -2.2% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.4% vs -1.0% NCT03596450
- -1.5% vs -1.1% NCT03596450
- Semaglutide (Rybelsus)
- -1.6% vs -0.2%−1.4 vs placeboNCT04109547
34 other results
- -1.5% vs -0.2% NCT04109547
- -1.1% vs -0.2% NCT04109547
- -0.7% vs -0.1% NCT03914326
- -1% vs -0.3% NCT02692716
- -1.2% vs -0.1% NCT02863419
- -1.2% vs -0.2% NCT03021187
- -0.9% vs -0.2% NCT03021187
- -0.6% vs -0.2% NCT03021187
- -1.5% vs 0.1% NCT03018028
- -1.4% vs 0.1% NCT03018028
- -1% vs 0.1% NCT03018028
- -1.1% vs -0.7% NCT02607865
- -1.3% vs -0.9% NCT02863328
- -1.2% vs -0.7% NCT02607865
- -0.9% vs -0.7% NCT02607865
- -1% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -1.8% vs -1.4% NCT03015220
- -2% vs -1.6% NCT03015220
- -1.4% vs -1.4% NCT03015220
- -1.7% vs -1.6% NCT03015220
- -0.8% vs -1.4% NCT03015220
- -1.1% vs -1.6% NCT03015220
- -0.2% vs 0% NCT02849080
- -1.3% vs -0.8% NCT02849080
- -2.0% vs -0.4% NCT01923181
- -1.8% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.7% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.2% vs -0.4% NCT01923181
- -0.9% vs -0.4% NCT01923181
- -1.2% vs -1.0% NCT05035082
Body weight, change (kg)
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -6.5 vs -2.3 NCT02648204
- -5.2 vs 1.1 NCT02128932
- -5.8 vs -2 NCT03191396
- -4.3 vs -1.9 NCT01930188
- -3.5 vs 1.1 NCT02128932
- -4.2 vs 2.9 NCT03689374
- -4.2 vs -0.4 NCT03061214
- -4.6 vs -2.3 NCT02648204
- -3 vs -0.4 NCT03061214
- -5.7 vs -4.3 NCT03136484
- -8.0 vs 0.4 NCT05514535
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
- Semaglutide (Rybelsus)
- -4.2 vs -1.3−2.9 vs placeboNCT03914326
39 other results
- -4.2 vs -0.8 NCT02692716
- -4.4 vs -1 NCT02863419
- -3.8 vs 0.5 NCT03021187
- -3.1 vs -1.1 NCT04109547
- -2.2 vs 0.5 NCT03021187
- -2.9 vs -1 NCT03018028
- -0.8 vs -1 NCT03018028
- -2.2 vs -1.1 NCT04109547
- -0.9 vs 0.5 NCT03021187
- -2.4 vs -1.1 NCT03018028
- -1.2 vs -1.1 NCT03018028
- 0 vs -1 NCT03018028
- -1.1 vs -1.1 NCT04109547
- -0.4 vs -1.1 NCT03018028
- -3.2 vs -1 NCT02607865
- -4 vs -3.7 NCT02863328
- -3.5 vs -0.7 NCT02607865
- -3.8 vs -0.5 NCT04017832
- -2.8 vs -1 NCT02607865
- -2.5 vs -0.7 NCT02607865
- -2.9 vs -0.5 NCT04017832
- -1.8 vs -1 NCT02607865
- -1.6 vs -0.7 NCT02607865
- -1.7 vs 1 NCT03015220
- -2.2 vs 0.3 NCT03015220
- -0.9 vs 1 NCT03015220
- -1 vs 0.3 NCT03015220
- 0 vs 1 NCT03015220
- -1.4 vs -0.5 NCT04017832
- -0.1 vs 0.3 NCT03015220
- -2.6 vs -0.9 NCT02849080
- -6.9 vs -1.2 NCT01923181
- -5.9 vs -1.2 NCT01923181
- -8.3 vs -1.2 NCT01923181
- -5.8 vs -1.2 NCT01923181
- -4.9 vs -1.2 NCT01923181
- -2.9 vs -1.2 NCT01923181
- -2.0 vs -1.2 NCT01923181
- -3.9 vs -3.5 NCT05035082
HbA1c below 7%
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
- Semaglutide (Rybelsus)
- —Not posted · NCT04596631, expected 2026-08
Fasting plasma glucose, change
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.8 vs -1.9 NCT02648204
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.1 vs -1.1 NCT01930188
- -2.2 vs -1.9 NCT02648204
- -2.0 vs -2.1 NCT02128932
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- Semaglutide (Rybelsus)
- -1.9 vs -0.7−1.2 vs placeboNCT02863419
39 other results
- -1.6 vs -0.1 NCT03021187
- -1.9 vs -0.2 NCT02906930
- -2.0 vs -0.3 NCT02863419
- -1.6 vs -0.3 NCT02827708
- -1.4 vs 0.5 NCT03021187
- -1.1 vs -0.1 NCT03021187
- -1.5 vs -0.2 NCT02906930
- -1.1 vs 0.5 NCT03021187
- -0.8 vs -0.1 NCT03021187
- -0.9 vs -0.2 NCT02906930
- -0.5 vs 0.5 NCT03021187
- -2.3 vs 0.3 NCT03018028
- -2.4 vs -0.4 NCT03018028
- -1.6 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.1 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.6 vs -0.9 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.8 vs -1.0 NCT02607865
- -2.0 vs -2.1 NCT02863328
- -1.7 vs -0.9 NCT02607865
- -2 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.3 vs -1.0 NCT02607865
- -1.2 vs -0.9 NCT02607865
- -2.7 vs -2.2 NCT03015220
- -1.8 vs -0.5 NCT04017832
- -1.1 vs -0.9 NCT02607865
- -1.0 vs -1.0 NCT02607865
- -0.8 vs -0.9 NCT02607865
- -2.2 vs -1.8 NCT03015220
- -2.0 vs -1.8 NCT03015220
- -2.3 vs -2.2 NCT03015220
- -0.9 vs -1.8 NCT03015220
- -1.0 vs -0.5 NCT04017832
- -1.2 vs -2.2 NCT03015220
- -0.3 vs 0.0 NCT02849080
- -2.4 vs -1.4 NCT02849080
3-point MACE (% with event)
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Semaglutide (Rybelsus)
- 12% vs 13.8%−1.8 vs placeboNCT03914326
1 other result
- 3.8% vs 4.8% NCT02692716
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
41 other shared endpoints and safety
Coverage. Semaglutide (Ozempic): 45 of 45 rows · Semaglutide (Rybelsus): 44 of 45 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) Rows use multiple source trials | Semaglutide (Rybelsus) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg | -1.5 vs 1 Insulin Aspart kg @ 52wka,b NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-2 vs -1.5 Canagliflozin kg @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | -1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mga,b NCT02863328 · Phase 3 14 other source trials-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg NCT02607865 · Phase 3 -0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg NCT02607865 · Phase 3 -0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg NCT02607865 · Phase 3 -1.6 vs -0.4 placebo kg @ 52wk14 mg NCT02863419 · Phase 3 -1.4 vs 0.2 placebo kg @ 52wk14 mg NCT03021187 · Phase 3 -0.3 vs 0.2 placebo kg @ 52wk3 mg NCT03021187 · Phase 3 -0.8 vs 0.2 placebo kg @ 52wk7 mg NCT03021187 · Phase 3 -1 vs -0.3 Sitagliptin kg @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence -1.1 vs -0.4 placebo kg @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0 vs -0.4 placebo kg @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.3 vs -0.4 placebo kg @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0 vs 0.3 Dulaglutide kg @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| BMI absolute change · kg No placebo or comparator arm | -2.5 kg @ 40wk2.0 mg weeklyc,a,b,d NCT03989232 · Phase 3 show 1 more dose-2.1 kg @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | -1.3 kg @ 104wka,b,d NCT02849080 · Phase 3 · registry result, not featured evidence |
| DBP absolute change · mmHg | -0.4 vs -0.8 placebo mmHg @ 104wke,b,f NCT03819153 · Phase 3 1 other source trial-1.9 vs -1.4 Standard of Care mmHg @ 104wk NCT03596450 · Phase 4 · registry result, not featured evidence | -2 vs -2 placebo mmHg @ 26wk14 mgc,e,b,f NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-1 vs -2 placebo mmHg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 0 vs -2 placebo mmHg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -1.29 mmol/L @ 52wka,b NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-1.41 mmol/L @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | -2.4 mmol/L @ 52wk14 mg once dailyc,a,b NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-3.2 mmol/L @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -3 mmol/L @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points On-treatment without rescue medication | -1.7% (n=394) vs -1% (n=394) Canagliflozin @ 52wka,b,g On-treatment without rescue medication NCT03136484 · Phase 3 · registry result, not featured evidence · combination | -1.7% (n=48) vs -0.2% (n=49) placebo @ 26wk14 mgc,a,b,g NCT03018028 · Phase 3 · registry result, not featured evidence show 2 more doses-1.7% (n=49) vs -0.2% (n=49) placebo @ 26wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1.1% (n=49) vs -0.2% (n=49) placebo @ 26wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.23% (n=91) @ 52wka,b NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-0.86% (n=335) @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | -1.5% (n=497) @ 52wk14 mg once dailyc,a,b NCT04707469 · Phase 3 · registry result, not featured evidence show 5 more doses-0.4% (n=333) @ 52wk14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -2.1% (n=492) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1% (n=339) @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -1.9% (n=475) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -0.8% (n=345) @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c 6.5 or Less event count · % of participants | 47% (n=404) vs 22% (n=405) Exenatide ER @ 56wk*1.0 mga,b,h Yes NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 190 Participants as posted | 63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk*14 mgc,a,b,h NCT02906930 · Phase 3 · converted to % from 102 Participants as posted show 2 more doses47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg NCT02906930 · Phase 3 · converted to % from 76 Participants as posted 35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg NCT02906930 · Phase 3 · converted to % from 60 Participants as posted |
| HbA1c 7.0 or Less event count · % of participants | 81.6% (n=288) vs 28.7% (n=94) placebo @ 72wk*7.2 mgi,j,e,b,k NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 235 Participants as posted | 91.3% (n=46) vs 35.3% (n=51) placebo @ 26wk*40 mgc,i,j,e,b,k NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 42 Participants as posted show 6 more doses86.4% (n=44) vs 35.3% (n=51) placebo @ 26wk*40 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 38 Participants as posted 90.4% (n=52) vs 35.3% (n=51) placebo @ 26wk*40 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 47 Participants as posted 85.4% (n=48) vs 35.3% (n=51) placebo @ 26wk*20 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 41 Participants as posted 86% (n=57) vs 35.3% (n=51) placebo @ 26wk*10 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 49 Participants as posted 86.2% (n=58) vs 35.3% (n=51) placebo @ 26wk*5 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 50 Participants as posted 48.2% (n=56) vs 35.3% (n=51) placebo @ 26wk*2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence · converted to % from 27 Participants as posted |
| HbA1c Less Than 7 or Reduction Ge 1 event count · % of participants | 74.7% (n=430) vs 65.2% (n=462) Standard of Care @ 52wk*a,b Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 321 Participants as posted | 73.3% (n=326) vs 61.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*a,b Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 239 Participants as posted |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain event count · % of participants | 48.5% (n=410) vs 37.3% (n=426) Standard of Care @ 52wk*l,a,b Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 199 Participants as posted | 45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*l,a,b Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted |
| HbA1c Less Than 7% event count · % of participants | 56.7% (n=430) vs 48.9% (n=462) Standard of Care @ 52wk*a,b Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 244 Participants as posted | 58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*a,b Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 67.6% (n=480) @ 40wk2.0 mg weeklyc,a,b,m NCT03989232 · Phase 3 show 1 more dose57.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | 39.2% (n=536) @ 68wk14 mg once dailyc,a,b,m NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses58.9% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 49.9% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% event count · % of participants No placebo or comparator arm | 56.5% (n=92) @ 24wk*l,a,b,n Yes NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 52 Participants as posted | 56.1% (n=180) @ 104wk*l,a,b,n Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 101 Participants as posted |
| HbA1c Less Than or Equal to 6.5 event count · % of participants | 72.6% (n=288) vs 16% (n=94) placebo @ 72wk*7.2 mgi,o,e,b,p NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 209 Participants as posted | 39% (n=326) vs 23.2% (n=293) Other Oral Glucose-lowering Medication @ 52wk*i,o,e,b,p Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted 1 other source trial33% (n=230) vs 12.2% (n=238) Sitagliptin @ 52wk* Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 76 Participants as posted |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants No placebo or comparator arm | 51.7% (n=480) @ 40wk2.0 mg weeklyc,a,b,m NCT03989232 · Phase 3 show 1 more dose38.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | 23.6% (n=536) @ 68wk14 mg once dailyc,a,b,m NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses46.2% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 35.8% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Target Attainment event count · % of participants | 50.2% (n=430) vs 36.8% (n=462) Standard of Care @ 52wk*a,b Yes NCT03596450 · Phase 4 · registry result, not featured evidence · converted to % from 216 Participants as posted | 68.1% (n=326) vs 58.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*c,a,b NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 222 Participants as posted show 1 more dose54.9% (n=326) vs 40.3% (n=293) Other Oral Glucose-lowering Medication @ 52wk* NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 179 Participants as posted |
| HDL Cholesterol ratio to baseline · ratio | 1.04 vs 0.99 placebo ratio @ 52wke,b NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 1.04 vs 1.08 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | 1.01 vs 1.06 Empagliflozin 25 mg ratio @ 52wk14 mge,b NCT02863328 · Phase 3 15 other source trials1.01 vs 0.99 Sitagliptin ratio @ 52wk14 mg NCT02607865 · Phase 3 0.99 vs 0.99 Sitagliptin ratio @ 52wk3 mg NCT02607865 · Phase 3 1.01 vs 0.99 Sitagliptin ratio @ 52wk7 mg NCT02607865 · Phase 3 1.03 vs 1 placebo ratio @ 52wk14 mg NCT02863419 · Phase 3 1.01 vs 1 placebo ratio @ 52wk14 mg NCT03021187 · Phase 3 1.01 vs 1 placebo ratio @ 52wk3 mg NCT03021187 · Phase 3 0.98 vs 1 placebo ratio @ 52wk7 mg NCT03021187 · Phase 3 1.05 vs 1.02 placebo ratio NCT02692716 · Phase 3 1 vs 1.02 Sitagliptin ratio @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence 0.99 vs 1.04 placebo ratio @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1.05 vs 1.04 placebo ratio @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1.01 vs 1.04 placebo ratio @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 1.01 vs 1 Dulaglutide ratio @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.03 vs 1 Dulaglutide ratio @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.99 vs 1 Dulaglutide ratio @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Hypoglycemia Episodes Level 3 event count · count | 6 vs 14 Insuline Glargine U100 (Titrated) count @ 40wke,b,q NCT05514535 · Phase 3 · registry result, not featured evidence · combination | 88 vs 121 placebo count @ 265wke,b,q NCT03914326 · Phase 3 |
| LDL Cholesterol ratio to baseline · ratio | 0.99 vs 1.03 placebo ratio @ 52wke,b NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.96 vs 1.05 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | 0.97 vs 1.03 Empagliflozin 25 mg ratio @ 52wk14 mge,b NCT02863328 · Phase 3 15 other source trials0.99 vs 1.03 Sitagliptin ratio @ 52wk14 mg NCT02607865 · Phase 3 1.02 vs 1.03 Sitagliptin ratio @ 52wk3 mg NCT02607865 · Phase 3 0.99 vs 1.03 Sitagliptin ratio @ 52wk7 mg NCT02607865 · Phase 3 0.99 vs 1.06 placebo ratio @ 52wk14 mg NCT02863419 · Phase 3 0.95 vs 1 placebo ratio @ 52wk14 mg NCT03021187 · Phase 3 0.97 vs 1 placebo ratio @ 52wk3 mg NCT03021187 · Phase 3 0.96 vs 1 placebo ratio @ 52wk7 mg NCT03021187 · Phase 3 0.96 vs 0.97 placebo ratio NCT02692716 · Phase 3 0.97 vs 1.03 Sitagliptin ratio @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence 0.91 vs 1.06 placebo ratio @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.99 vs 1.06 placebo ratio @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.96 vs 1.06 placebo ratio @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.92 vs 0.91 Dulaglutide ratio @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.98 vs 0.91 Dulaglutide ratio @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.94 vs 0.91 Dulaglutide ratio @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| MALE event rate · % of participants | 0.9% (n=1767) vs 1.6% (n=1766) placebo*e,b,r NCT03819153 · Phase 3 · converted to % from 16 Participants as posted | 1.5% (n=4825) vs 2.1% (n=4825) placebo @ 265wk*e,b,r NCT03914326 · Phase 3 · converted to % from 71 Participants as posted |
| Non-fatal MI event count · % of participants | 2.9% (n=1767) vs 3.6% (n=1766) placebo*e,b,r NCT03819153 · Phase 3 · converted to % from 52 Participants as posted | 4% (n=4825) vs 5.2% (n=4825) placebo @ 265wk*e,b,r NCT03914326 · Phase 3 · converted to % from 191 Participants as posted |
| PPG Excursion absolute change · mmol/L | -0.7 vs -0.9 Insulin Aspart mmol/L @ 52wka,b NCT03689374 · Phase 3 · registry result, not featured evidence | -0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mga,b NCT02863328 · Phase 3 13 other source trials-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg NCT02607865 · Phase 3 -0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg NCT02607865 · Phase 3 -0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg NCT02607865 · Phase 3 -0.5 vs -0.4 placebo mmol/L @ 52wk14 mg NCT02863419 · Phase 3 -0.7 vs -0.3 placebo mmol/L @ 52wk14 mg NCT03021187 · Phase 3 -0.3 vs -0.3 placebo mmol/L @ 52wk3 mg NCT03021187 · Phase 3 -0.7 vs -0.3 placebo mmol/L @ 52wk7 mg NCT03021187 · Phase 3 -2 vs -0.1 placebo mmol/L @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.5 vs -0.1 placebo mmol/L @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.9 vs -0.1 placebo mmol/L @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Renal Death event count · % of participants | 0.3% (n=1767) vs 0.3% (n=1766) placebo*e,b,r NCT03819153 · Phase 3 · converted to % from 5 Participants as posted | 0% (n=4825) vs 0.1% (n=4825) placebo @ 265wk*e,b,r NCT03914326 · Phase 3 · converted to % from 1 Participants as posted |
| SBP absolute change · mmHg | -3.9 vs -1.4 placebo mmHg @ 104wke,b,f NCT03819153 · Phase 3 1 other source trial-3 vs -2.8 Standard of Care mmHg @ 104wk NCT03596450 · Phase 4 · registry result, not featured evidence | -4 vs -2 placebo mmHg @ 26wk14 mgc,e,b,f NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-2 vs -2 placebo mmHg @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 1 vs -2 placebo mmHg @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| SF-36 Bodily Pain absolute change · score Bodily pain | 1.54 vs 1.69 Dulaglutide score @ 40wk1.0 mgc,a,b,s NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose0.96 vs 1.69 Dulaglutide score @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence | 0.51 vs 0.22 Sitagliptin score @ 26wk14 mgc,a,b,s NCT04017832 · Phase 3 · registry result, not featured evidence show 2 more doses-0.37 vs 0.22 Sitagliptin score @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence -0.06 vs 0.22 Sitagliptin score @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence |
| SF-36 General Health absolute change · score General health | 2.52 vs 1.86 Dulaglutide score @ 40wk1.0 mgc,a,b,s NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose2.65 vs 1.86 Dulaglutide score @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence | 1.95 vs 0.95 Sitagliptin score @ 26wk14 mgc,a,b,s NCT04017832 · Phase 3 · registry result, not featured evidence show 2 more doses1.04 vs 0.95 Sitagliptin score @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 1.47 vs 0.95 Sitagliptin score @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence |
| SF-36 Vitality absolute change · score Vitality | 1.97 vs 2.14 Dulaglutide score @ 40wk1.0 mgc,a,b,s NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose1.23 vs 2.14 Dulaglutide score @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence | 1.21 vs 0.33 Sitagliptin score @ 26wk14 mgc,a,b,s NCT04017832 · Phase 3 · registry result, not featured evidence show 2 more doses0.84 vs 0.33 Sitagliptin score @ 26wk7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 0.44 vs 0.33 Sitagliptin score @ 26wk3 mg NCT04017832 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -2.1 vs -2.1 Insulin Aspart mmol/L @ 52wka,b NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-2.8 vs -1.9 Canagliflozin mmol/L @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | -2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mga,b NCT02863328 · Phase 3 13 other source trials-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg NCT02607865 · Phase 3 -1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg NCT02607865 · Phase 3 -1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg NCT02607865 · Phase 3 -2.2 vs -0.9 placebo mmol/L @ 52wk14 mg NCT02863419 · Phase 3 -2 vs -0.9 placebo mmol/L @ 52wk14 mg NCT03021187 · Phase 3 -1.6 vs -0.9 placebo mmol/L @ 52wk3 mg NCT03021187 · Phase 3 -1.7 vs -0.9 placebo mmol/L @ 52wk7 mg NCT03021187 · Phase 3 -3.1 vs 0 placebo mmol/L @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1.7 vs 0 placebo mmol/L @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -2.2 vs 0 placebo mmol/L @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Total Cholesterol ratio to baseline · ratio | 0.96 vs 1 placebo ratio @ 52wke,b NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials1 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.96 vs 1.03 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | 0.97 vs 1.01 Empagliflozin 25 mg ratio @ 52wk14 mge,b NCT02863328 · Phase 3 15 other source trials0.98 vs 1.01 Sitagliptin ratio @ 52wk14 mg NCT02607865 · Phase 3 1 vs 1.01 Sitagliptin ratio @ 52wk3 mg NCT02607865 · Phase 3 0.99 vs 1.01 Sitagliptin ratio @ 52wk7 mg NCT02607865 · Phase 3 0.98 vs 1.02 placebo ratio @ 52wk14 mg NCT02863419 · Phase 3 0.95 vs 1 placebo ratio @ 52wk14 mg NCT03021187 · Phase 3 0.98 vs 1 placebo ratio @ 52wk3 mg NCT03021187 · Phase 3 0.97 vs 1 placebo ratio @ 52wk7 mg NCT03021187 · Phase 3 0.97 vs 0.98 placebo ratio NCT02692716 · Phase 3 0.96 vs 1.01 Sitagliptin ratio @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence 0.93 vs 1.01 placebo ratio @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.99 vs 1.01 placebo ratio @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.95 vs 1.01 placebo ratio @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.94 vs 0.93 Dulaglutide ratio @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.98 vs 0.93 Dulaglutide ratio @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.95 vs 0.93 Dulaglutide ratio @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Triglyceride ratio to baseline · ratio | 0.8 vs 0.95 placebo ratio @ 52wke,b NCT04560998 · Phase 3 · registry result, not featured evidence 2 other source trials0.9 vs 1 Insulin Aspart ratio @ 52wk NCT03689374 · Phase 3 · registry result, not featured evidence 0.86 vs 0.92 Canagliflozin ratio @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | 0.89 vs 0.9 Empagliflozin 25 mg ratio @ 52wk14 mge,b NCT02863328 · Phase 3 15 other source trials0.93 vs 0.98 Sitagliptin ratio @ 52wk14 mg NCT02607865 · Phase 3 1 vs 0.98 Sitagliptin ratio @ 52wk3 mg NCT02607865 · Phase 3 0.97 vs 0.98 Sitagliptin ratio @ 52wk7 mg NCT02607865 · Phase 3 0.87 vs 0.97 placebo ratio @ 52wk14 mg NCT02863419 · Phase 3 0.86 vs 0.97 placebo ratio @ 52wk14 mg NCT03021187 · Phase 3 0.93 vs 0.97 placebo ratio @ 52wk3 mg NCT03021187 · Phase 3 0.94 vs 0.97 placebo ratio @ 52wk7 mg NCT03021187 · Phase 3 0.92 vs 0.97 placebo ratio NCT02692716 · Phase 3 0.89 vs 0.91 Sitagliptin ratio @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence 0.86 vs 0.82 placebo ratio @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.86 vs 0.82 placebo ratio @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.84 vs 0.82 placebo ratio @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.87 vs 0.88 Dulaglutide ratio @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.89 vs 0.88 Dulaglutide ratio @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 0.87 vs 0.88 Dulaglutide ratio @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| UACR ratio to baseline · ratio | 0.6 vs 0.89 placebo ratio @ 104wke,b,f NCT03819153 · Phase 3 | 0.86 vs 1.19 placebo ratio @ 26wk14 mge,b,f NCT02827708 · Phase 3 |
| VLDL Cholesterol ratio to baseline · ratio | 0.95 vs 0.86 placebo ratio @ 34wk21.6 mgc,t,a,u NCT05144984 · Phase 2 · registry result, not featured evidence show 4 more doses0.72 vs 0.86 placebo ratio @ 34wk2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.75 vs 0.86 placebo ratio @ 34wk2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.78 vs 0.86 placebo ratio @ 34wk2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 0.76 vs 0.86 placebo ratio @ 34wk2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination | 0.91 vs 0.94 Sitagliptin ratio @ 78wk14 mgc,t,a,u NCT02607865 · Phase 3 show 2 more doses0.94 vs 0.94 Sitagliptin ratio @ 78wk7 mg NCT02607865 · Phase 3 0.95 vs 0.94 Sitagliptin ratio @ 78wk3 mg NCT02607865 · Phase 3 |
| Waist Circumference Change absolute change · cm | -3.3 vs 2.1 Insulin Aspart cm @ 52wka,b NCT03689374 · Phase 3 · registry result, not featured evidence 1 other source trial-4.2 vs -3 Canagliflozin cm @ 52wk NCT03136484 · Phase 3 · registry result, not featured evidence · combination | -3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mga,b NCT02863328 · Phase 3 14 other source trials-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg NCT02607865 · Phase 3 -1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg NCT02607865 · Phase 3 -2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg NCT02607865 · Phase 3 -4.4 vs -1.7 placebo cm @ 52wk14 mg NCT02863419 · Phase 3 -4 vs 0.3 placebo cm @ 52wk14 mg NCT03021187 · Phase 3 -0.8 vs 0.3 placebo cm @ 52wk3 mg NCT03021187 · Phase 3 -2.3 vs 0.3 placebo cm @ 52wk7 mg NCT03021187 · Phase 3 -2.6 vs -0.7 Sitagliptin cm @ 52wk NCT02849080 · Phase 3 · registry result, not featured evidence -2.7 vs -0.9 placebo cm @ 52wk14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0.2 vs -0.9 placebo cm @ 52wk3 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1 vs -0.9 placebo cm @ 52wk7 mg NCT03018028 · Phase 3 · registry result, not featured evidence -1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg NCT03015220 · Phase 3 · registry result, not featured evidence -0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg NCT03015220 · Phase 3 · registry result, not featured evidence |
| Waist Circumference Change absolute change · cm No placebo or comparator arm | -5.9 cm @ 40wk2.0 mg weeklyc,a,b,d NCT03989232 · Phase 3 show 1 more dose-5.2 cm @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | -2.5 cm @ 104wka,b,d NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight percent change · % of baseline | -4.47% (n=389) vs -2.68% (n=386) Standard of Care @ 104wkl,a,b NCT03596450 · Phase 4 · registry result, not featured evidence | -3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wkl,a,b NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -3.85 kg @ 52wka,b NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-3.77 kg @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 | -4.4 kg @ 52wk14 mg once dailyc,a,b NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses-8.3 kg @ 52wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence -7.1 kg @ 52wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight Loss 10% event count · % of participants | 62.9% (n=291) vs 11.6% (n=95) placebo @ 72wk*7.2 mge,b,p Yes NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 183 Participants as posted | 6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*e,b,p Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted |
| Weight Loss 10% responder rate · % of participants No placebo or comparator arm | 28.4% (n=480) @ 40wk2.0 mg weeklyc,a,b,m NCT03989232 · Phase 3 show 1 more dose22.6% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | 14.3% (n=536) @ 68wk14 mg once dailyc,a,b,m NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses34.7% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 29.4% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight Loss 5% event count · % of participants | 86.3% (n=291) vs 34.7% (n=95) placebo @ 72wk*7.2 mgo,e,b,p Yes NCT05649137 · Phase 3 · registry result, not featured evidence · converted to % from 251 Participants as posted | 36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*o,e,b,p Yes NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted 1 other source trial27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk* Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted |
| Weight Loss 5% responder rate · % of participants No placebo or comparator arm | 59.2% (n=480) @ 40wk2.0 mg weeklyc,a,b,m NCT03989232 · Phase 3 show 1 more dose51.3% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 | 42.2% (n=536) @ 68wk14 mg once dailyc,a,b,m NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses65.7% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 58.5% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Weight Loss 5% event count · % of participants No placebo or comparator arm | 60.9% (n=92) @ 24wk*l,a,b,n Yes NCT05533632 · Phase 4 · registry result, not featured evidence · converted to % from 56 Participants as posted | 33.9% (n=180) @ 104wk*l,a,b,n Yes NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 61 Participants as posted |
| Dropout rate | 1.3%1.0 mgv NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination | 6.9%14 mgw NCT02906930 · Phase 3 show 39 more results8%7 mg NCT02906930 · Phase 3 3.4%3 mg NCT02906930 · Phase 3 2.7%14 mg NCT02863328 · Phase 3 5.8%14 mg NCT02607865 · Phase 3 6.4%7 mg NCT02607865 · Phase 3 7.1%3 mg NCT02607865 · Phase 3 2.8%14 mg NCT02863419 · Phase 3 3.1%14 mg NCT02827708 · Phase 3 3.3%14 mg NCT03021187 · Phase 3 4.9%7 mg NCT03021187 · Phase 3 5.4%3 mg NCT03021187 · Phase 3 1.5% NCT03914326 · Phase 3 0.3% NCT02692716 · Phase 3 11.8% NCT05035082 · Phase 4 · registry result, not featured evidence 5.4%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 5.6%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.4%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 7.2%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 5%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.6%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 2.1%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 2.3%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.5%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 2.3%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 11.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 11.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 5.7%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 8.6%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —1.0 mgv NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination | —14 mgw NCT02906930 · Phase 3 show 39 more results—7 mg NCT02906930 · Phase 3 —3 mg NCT02906930 · Phase 3 —14 mg NCT02863328 · Phase 3 —14 mg NCT02607865 · Phase 3 —7 mg NCT02607865 · Phase 3 —3 mg NCT02607865 · Phase 3 —14 mg NCT02863419 · Phase 3 —14 mg NCT02827708 · Phase 3 —14 mg NCT03021187 · Phase 3 —7 mg NCT03021187 · Phase 3 —3 mg NCT03021187 · Phase 3 — NCT03914326 · Phase 3 — NCT02692716 · Phase 3 — NCT05035082 · Phase 4 · registry result, not featured evidence —14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —14 mg NCT04017832 · Phase 3 · registry result, not featured evidence —7 mg NCT04017832 · Phase 3 · registry result, not featured evidence —3 mg NCT04017832 · Phase 3 · registry result, not featured evidence —14 mg NCT04109547 · Phase 3 · registry result, not featured evidence —7 mg NCT04109547 · Phase 3 · registry result, not featured evidence —3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence —14 mg NCT03018028 · Phase 3 · registry result, not featured evidence —7 mg NCT03018028 · Phase 3 · registry result, not featured evidence —3 mg NCT03018028 · Phase 3 · registry result, not featured evidence —14 mg NCT03015220 · Phase 3 · registry result, not featured evidence —7 mg NCT03015220 · Phase 3 · registry result, not featured evidence —3 mg NCT03015220 · Phase 3 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —20 mg NCT01923181 · Phase 2 · registry result, not featured evidence —10 mg NCT01923181 · Phase 2 · registry result, not featured evidence —5 mg NCT01923181 · Phase 2 · registry result, not featured evidence —2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.6%1.0 mgv NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination | 1.1%14 mgw NCT02906930 · Phase 3 show 39 more results1.7%7 mg NCT02906930 · Phase 3 2.9%3 mg NCT02906930 · Phase 3 6.6%14 mg NCT02863328 · Phase 3 9.5%14 mg NCT02607865 · Phase 3 10.1%7 mg NCT02607865 · Phase 3 13.7%3 mg NCT02607865 · Phase 3 10.9%14 mg NCT02863419 · Phase 3 10.4%14 mg NCT02827708 · Phase 3 6.6%14 mg NCT03021187 · Phase 3 10.5%7 mg NCT03021187 · Phase 3 13.6%3 mg NCT03021187 · Phase 3 47.9% NCT03914326 · Phase 3 18.9% NCT02692716 · Phase 3 10.2% NCT05035082 · Phase 4 · registry result, not featured evidence 9.9%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.2%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 10.7%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 3%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.9%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 7.7%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 4.6%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 9.5%Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence 14.2%Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence 9%Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 0%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 4.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 5.4%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 3%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 6.9%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 0%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 1.4%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1.0 mgv nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination | 14 mgw nausea 16% (placebo 5.6%) vomiting 6.9% (placebo 2.2%) decreased appetite 5.1% (placebo 0.6%) NCT02906930 · Phase 3 show 38 more results7 mg nasopharyngitis 6.3% (placebo 3.4%) headache 5.7% (placebo 5.1%) diarrhoea 5.1% (placebo 2.2%) NCT02906930 · Phase 3 3 mg diarrhoea 8.6% (placebo 2.2%) nausea 8% (placebo 5.6%) nasopharyngitis 5.7% (placebo 3.4%) NCT02906930 · Phase 3 14 mg nausea 19.3% (placebo 3.5%) diarrhoea 15.1% (placebo 7.7%) nasopharyngitis 14.4% (placebo 10.6%) NCT02863419 · Phase 3 14 mg nausea 19% (placebo 7.5%) constipation 11.7% (placebo 3.7%) vomiting 11.7% (placebo 1.2%) NCT02827708 · Phase 3 14 mg nausea 22.7% (placebo 7.1%) diarrhoea 14.4% (placebo 6%) decreased appetite 12.7% (placebo 1.1%) NCT03021187 · Phase 3 7 mg nausea 16.6% (placebo 7.1%) diarrhoea 12.2% (placebo 6%) nasopharyngitis 11.6% (placebo 14.7%) NCT03021187 · Phase 3 3 mg nasopharyngitis 14.7% (placebo 14.7%) nausea 11.4% (placebo 7.1%) diarrhoea 8.7% (placebo 6%) NCT03021187 · Phase 3 diabetic retinopathy 19.5% (placebo 19.3%) covid-19 15.7% (placebo 16.1%) nausea 7.1% (placebo 1.3%) NCT03914326 · Phase 3 14 mg once daily nausea 18% diarrhoea 12.4% covid-19 11.8% NCT04707469 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 27.3% vomiting 18.2% diarrhoea 14.2% NCT04707469 · Phase 3 · registry result, not featured evidence 25 mg once daily nausea 27.2% vomiting 17% diarrhoea 12.9% NCT04707469 · Phase 3 · registry result, not featured evidence 14 mg diarrhoea 13.3% nausea 12.2% decreased appetite 9.4% NCT04017832 · Phase 3 · registry result, not featured evidence 7 mg nausea 10.9% diarrhoea 8.9% decreased appetite 8.4% NCT04017832 · Phase 3 · registry result, not featured evidence 3 mg nausea 10% diarrhoea 8.3% upper respiratory tract infection 7.2% NCT04017832 · Phase 3 · registry result, not featured evidence 14 mg decreased appetite 10.9% (placebo 0%) diarrhoea 9.3% (placebo 1.5%) upper respiratory tract infection 7% (placebo 4.6%) NCT04109547 · Phase 3 · registry result, not featured evidence 7 mg diarrhoea 9.2% (placebo 1.5%) upper respiratory tract infection 9.2% (placebo 4.6%) lipase increased 8.5% (placebo 0%) NCT04109547 · Phase 3 · registry result, not featured evidence 3 mg upper respiratory tract infection 8.5% (placebo 4.6%) lipase increased 5.4% (placebo 0%) nausea 4.6% (placebo 1.5%) NCT04109547 · Phase 3 · registry result, not featured evidence nausea 20.9% nasopharyngitis 10.3% headache 9.9% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 22.9% nasopharyngitis 13.4% diarrhoea 11.5% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 17% diarrhoea 10% nasopharyngitis 7% NCT02849080 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 18.8% (placebo 28.6%) constipation 12.5% (placebo 6.1%) decreased appetite 12.5% (placebo 0%) NCT03018028 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 16.3% (placebo 28.6%) constipation 12.2% (placebo 6.1%) nausea 10.2% (placebo 2%) NCT03018028 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 20.4% (placebo 28.6%) constipation 10.2% (placebo 6.1%) periarthritis 10.2% (placebo 4.1%) NCT03018028 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 30% constipation 15.4% nausea 9.2% NCT03015220 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 29.5% constipation 12.1% decreased appetite 9.1% NCT03015220 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 26% constipation 9.2% influenza 6.9% NCT03015220 · Phase 3 · registry result, not featured evidence 40 mg nausea 33.8% (placebo 1.4%) vomiting 19.7% (placebo 4.2%) decreased appetite 14.1% (placebo 1.4%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 35.7% (placebo 1.4%) vomiting 22.9% (placebo 4.2%) diarrhoea 17.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 32.9% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 15.7% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 20 mg nausea 35.7% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 17.1% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 10 mg nausea 33.3% (placebo 1.4%) diarrhoea 23.2% (placebo 9.9%) vomiting 20.3% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 5 mg nausea 14.3% (placebo 1.4%) headache 12.9% (placebo 5.6%) diarrhoea 10% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 2.5 mg nausea 12.9% (placebo 1.4%) nasopharyngitis 8.6% (placebo 12.7%) diarrhoea 7.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dAssessment timepoints differ: 40 weeks versus 104 weeks.
- ePopulation context differs: registered conditions differ.
- fAssessment timepoints differ: 104 weeks versus 26 weeks.
- gAssessment timepoints differ: 52 weeks versus 26 weeks.
- hAssessment timepoints differ: 56 weeks versus 26 weeks.
- iThe reported result categories differ.
- jTrial phases differ: Phase 3 versus Phase 2.
- kAssessment timepoints differ: 72 weeks versus 26 weeks.
- lTrial phases differ: Phase 4 versus Phase 3.
- mAssessment timepoints differ: 40 weeks versus 68 weeks.
- nAssessment timepoints differ: 24 weeks versus 104 weeks.
- oTrial phases differ: Phase 3 versus Phase 4.
- pAssessment timepoints differ: 72 weeks versus 52 weeks.
- qAssessment timepoints differ: 40 weeks versus 265 weeks.
- rThe assessment timepoint is not available for both results.
- sAssessment timepoints differ: 40 weeks versus 26 weeks.
- tTrial phases differ: Phase 2 versus Phase 3.
- uAssessment timepoints differ: 34 weeks versus 78 weeks.
- vPopulation comparability has not been reviewed for 43 of these studies.
- wPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 10 more results
show 10 more results
show 1 more result
show 4 more results
show 1 more result
show 4 more results
show 4 more results
show 4 more results
show 4 more results
+ 74 further endpoints in the CSV export.
Semaglutide (Rybelsus)
show 11 more results
show 9 more results
show 10 more results
show 36 more results
show 39 more results
show 1 more result
show 10 more results
show 10 more results
show 12 more results
show 12 more results
show 13 more results
show 13 more results
+ 83 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: July 2028 · NCT07073053 (registry estimate)
Reported efficacy
Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)
Result source: NCT04560998
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2029 · NCT07254572 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Semaglutide (Ozempic) | Semaglutide (Rybelsus) |
|---|---|---|
| LDL-C, % change | —Not reported | —Not reported |
| Non-HDL-C, % change | —Not reported | —Not reported |
| ApoB, % change | —Not reported | —Not reported |
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Rybelsus)
- —Not reported
Non-HDL-C, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Rybelsus)
- —Not reported
ApoB, % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Rybelsus)
- —Not reported
Lp(a), % change
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Rybelsus)
- —Not reported
3-point MACE (% with event)
- Semaglutide (Ozempic)
- —Not reported
- Semaglutide (Rybelsus)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Semaglutide (Rybelsus): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Semaglutide (Ozempic): 3 of 4 rows · Semaglutide (Rybelsus): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) |
|---|---|
| Dropout rate | 7.6%a NCT04560998 · Phase 3 |
| Discontinued due to AEs | —a NCT04560998 · Phase 3 |
| Serious AEs | 18.7%a NCT04560998 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Semaglutide (Ozempic)'s landscape · Semaglutide (Rybelsus)'s landscape